Company Overview of Oryzon Genomics S.A.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies to treat oncology and neurodegenerative diseases. Its clinical-stage product candidates include ORY-1001, an oncology product, which is in Phase I/IIA clinical trial for treating acute leukemia disease; and ORY-2001, a dual selective LSD1 and MAO-B inhibitor that is in Phase I clinical trial for Alzheimer and other diseases. The company has collaboration agreement with ROCHE for the development of its product, ORY-1001. Oryzon Genomics S.A. was founded in 2000 and is headquartered in Barcelona, Spain.
Sant Ferran 74
Cornella de Llobregat
Founded in 2000
Key Executives for Oryzon Genomics S.A.
Co-Founder, Chairman and Chief Executive Officer
Total Annual Compensation: €52.0K
First Deputy President and Chief Scientific Officer
Total Annual Compensation: €52.0K
Compensation as of Fiscal Year 2015.
Oryzon Genomics S.A. Key Developments
Oryzon Genomics to Present ORY-2001 Preliminary Top Line Phase I Clinical Data
Jan 25 17
Oryzon Genomics announced that it will present preliminary top-line clinical results from the first-in-man clinical trial to assess safety, tolerability and pharmacokinetics of ORY-2001, a novel epigenetic drug for treatment of neurodegenerative diseases, at the 13th ADPD International Conference to be held in Vienna, Austria from March 29, 2017 to April 2, 2017. Preliminary data on safety, pharmacokinetics, target engagement and surrogate biomarker in peripheral samples in the SAD and MAD phases in 88 healthy volunteers administered with different doses of ORY-2001 will be presented by Dr. César Molinero, Medical and Clinical Operations Director of the company on March 31st on the symposium 38 - short oral session 03 - short oral presentations of selected posters - that starts at 17.15 PM CET. ORY-2001 is a highly selective dual LSD1-MAOB inhibitor. The molecule, which focuses on cognitive decline and memory loss, has a good safety profile and therapeutic index in preclinical trials. In nontransgenic AD mouse models, long-term treatments with the drug demonstrated a marked cognitive improvement. The company has also recently presented data that supports the potential application of this experimental drug in other CNS neuroinflammatory disorders such as Multiple Sclerosis. LSD1 is an epigenetic modulator, which regulates histone methylation. Epigenetic approaches to modify the progression of various neurodegenerative diseases focus on producing changes in patterns of gene expression in neurons and also in glia cells and are of interest for the pharmaceutical industry. Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first forerunner program licensed to Roche (ORY-1001/RG6016) that has recently finished Phase I/IIA in acute leukemia and is currently being explored in an ongoing Phase I clinical trial in Small Cell Lung Cancer that validates the platform scientifically and clinically. This Platform has so far produced two additional programs: ORY-2001, already in clinical development with multiple indication opportunities that is pioneering the histone demethylases field in neurodegenerative disorders; and ORY-3001, also against LSD1, currently in preclinical development for a yet undisclosed non-oncological orphan indication.
Oryzon Genomics S.A. Presents at Noble Financial Capital Markets 13th Annual Small Cap and Emerging Growth Investor Conference, Jan-30-2017
Jan 19 17
Oryzon Genomics S.A. Presents at Noble Financial Capital Markets 13th Annual Small Cap and Emerging Growth Investor Conference, Jan-30-2017 . Venue: Boca Raton Resort & Club, 501 E Camino Real, Boca Raton, FL 33432, United States.
Oryzon Genomics Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer
Jan 9 17
Oryzon Genomics announced that the first patient has been treated in the Phase I study of RG6016, a LSD1 inhibitor, in small cell lung cancer (SCLC). This clinical trial is executed by Roche. Roche has started a dose finding and expansion study of RG6016 administered orally in participants with relapsed, extensive-stage disease small cell lung cancer (ED SCLC). The study initially will be conducted in several European countries and Canada. This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RG6016 in participants with relapsed ED SCLC. This dose escalation and expansion study plans to determine the maximum tolerated dose and/or optimal biological dose as a recommended Phase 2 dose for RG6016, based on the safety, tolerability, pharmacokinetic and pharmacodynamic profiles observed after oral administration of the drug Roche licensed in the global development and commercial rights to RG6016, previously known as ORY-1001 in 2014. After completion of the first trial in Acute Leukemia, sponsored by Oryzon and currently in the process of final data analysis and closing, Roche is solely responsible for the further clinical development of RG6016. Preliminary efficacy data obtained in the Phase IIA arm of this first clinical study in Leukemia was presented at the ASH meeting in San Diego last December.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 18, 2016